Fresenius | FRE - Cash And Equivalent


Fresenius reported EUR2.06B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Akzo Nobel EUR 2.76B 1.14B Mar/2026
Alcon AG USD 1.58B 80M Mar/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
BASF EUR 7.8B 4.71B Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
Beiersdorf EUR 1.2B 33M Dec/2025
DaVita Healthcare Partners USD 668.96M 24.72M Jun/2026
Demant DKK 1.33B 188M Dec/2025
E.ON EUR 4.87B 1.83B Mar/2026
Essilor EUR 3.54B 758M Dec/2025
Fresenius EUR 2.06B 752M Mar/2026
Fresenius Medical Care EUR 1.06B 177.89M Jun/2026
Getinge SEK 2.05B 909M Jun/2026
Givaudan CHF 603M 3M Jun/2024
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GN Store Nord DKK 865M 254M Mar/2026
GRIFOLS EUR 513M 189M Jun/2026
Hikma Pharmaceutical USD 217M 19M Dec/2025
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.74B 415M Mar/2026
Novartis USD 7.62B 739M Jun/2026
Philips EUR 1.79B 803M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
RWE EUR 6.86B 873M Mar/2026
Sanofi EUR 6.35B 806M Jun/2026